OS

Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, HCC, Bristol Myers Squibb, OS, BMY, TKI, Ipilimumab, Patient, Checkmate, Sorafenib, Immunotherapy, Survival, Nivolumab, Pharmaceutical industry

The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib.

Key Points: 
  • The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib.
  • The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals identified.
  • “Advanced stage liver cancer patients remain in need of additional treatment options that may help improve survival,” said Dana Walker, M.D., M.S.C.E., vice president, global program lead, gastrointestinal and genitourinary cancers, Bristol Myers Squibb.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -9DW clinical trial.

Plus Advances the Development of Next-Generation Vision Models, Built on NVIDIA DRIVE, for AI Processing in its Self-Driving Software

Retrieved on: 
Monday, March 18, 2024
Trucking, Automotive, Technology, Logistics, Supply Chain Management, Transport, Autonomous Driving, Vehicles, Artificial Intelligence, OS, SOC, BEV, DRIVE, Nvidia Drive, Perception, 3D, SuperDrive, ASIL D, AI, Plus, LLM, Multimedia, NVIDIA, Automotive industry, Movement, Thor, Video game

Plus, a global provider of autonomous driving software solutions, is collaborating with NVIDIA on the advanced development of its AI-driven vision models.

Key Points: 
  • Plus, a global provider of autonomous driving software solutions, is collaborating with NVIDIA on the advanced development of its AI-driven vision models.
  • Plus’s state-of-the-art vision models, will run on the NVIDIA DRIVE Thor™ by automotive-grade and safety-compliant compute platform for future generations of Plus’s Level 4 solution, SuperDrive™.
  • This immense computing power will be used to help the Plus autonomous driving system understand the world around the vehicle and make safe driving decisions.
  • “Plus’s SuperDrive platform, powered by NVIDIA DRIVE Thor, will seamlessly manage the extensive onboard perception tasks essential for safe, robust self-driving trucks.”

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, March 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, OS, Chemoradiotherapy, CRT, Obstetrics, Congress, Gynaecology, CPS, Survival, Disease, Progression-free survival, Data monitoring committee, Cervical cancer, Patient, Neoplasm, Merck & Co., Overalls, Humanitas University, Bevacizumab, MRK, Cancer, ESMO, PFS, FIGO, PD-L1, Food, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
  • As previously reported , KEYNOTE-A18 met its other primary endpoint of progression-free survival (PFS) in 2023.

Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer

Retrieved on: 
Saturday, March 16, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, OS, Food and Drug Administration, Endometrial cancer, Progression-free survival, Risk, GSK, Patient, Aes, Death, MD, Nature, Clinical trial, Copenhagen University Hospital, Gynecologic Oncology (journal), Division, PFS, Food, Pharmaceutical industry

2 Exploratory analyses of OS in dMMR/MSI-H and OS in MMRp/MSS populations were pre-specified with no planned hypothesis testing.

Key Points: 
  • 2 Exploratory analyses of OS in dMMR/MSI-H and OS in MMRp/MSS populations were pre-specified with no planned hypothesis testing.
  • RUBY Part 2: addition of niraparib to dostarlimab-gxly in maintenance setting significantly improved PFS in first-line primary advanced or recurrent endometrial cancer compared to chemotherapy alone, meeting the primary endpoint of the trial.
  • Discontinuation of dostarlimab-gxly or placebo due to a TEAE occurred in 24.1% of patients in the treatment arm and 5.2% of patients in the control arm.
  • Discontinuation of niraparib or placebo due to a treatment-emergent AE occurred in 15.7% of patients in the treatment arm and 4.2% of patients in the control arm.

Agenus Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Oncology, OS, BOT, Colitis, Inc., Colorectal cancer, PD, RECIST, IST, Partnership, RAS, Patient, MSI, FOLFIRINOX, BMS, Melanoma, MSS, BAL, Cancer, CRC, NLM, TIGIT, Liver disease, Pharmaceutical industry

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
  • “In 2023, Agenus made significant advances across our BOT/BAL development program.
  • $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023.
  • For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share.

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Retrieved on: 
Monday, March 11, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Research, Software, General Health, Genetics, Health Technology, Science, Data Management, Clinical Trials, Biopsy, OS, HER2, Cancer, Radiation, Kingdom of Poland, Anthracycline, Survival, Disease, Neoadjuvant therapy, CBM, International Cancer Genome Consortium, TNM, University, Patient, Rated R, NGS, Biomarker, MSI, Artificial intelligence, Standard of care, DFS, TRI, MD, Medicine, TRG, Platinum, Publication, Biosimulation, OGA, Whole genome sequencing, PD-L1, Taxane, Medical imaging

The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).

Key Points: 
  • The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
  • Despite progress in gastroesophageal cancer therapy, only a small proportion of patients attain long-term survival.
  • This study concluded that TRI scores for gastroesophageal adenocarcinoma patients predict OS and DFS beyond clinical factors.
  • These results highlight the clinical value of employing Cellworks biosimulation for personalized therapy selection and warrant additional clinical evaluation.

Ezurio Announces the Sona™ MT320: The First Industrial Grade Wi-Fi 6 + Bluetooth Module Powered by MediaTek Filogic 320 Technology

Retrieved on: 
Thursday, April 4, 2024
Sona, OS, FCC, Certification, MediaTek, CE, Bed, SDIO, Wi-Fi, Partnership, Internet of things, Tungsten, UKCA, Linux, SMARC, SMT, Wi-Fi 6, WPA3, HD, Pump, Bluetooth Special Interest Group, Bluetooth, Mobile phone

AKRON, Ohio, April 4, 2024 /PRNewswire/ -- Ezurio, a global leader in connectivity, today announces the upcoming Sona™ MT320 , the latest addition to their growing Wi-Fi 6 module portfolio.

Key Points: 
  • AKRON, Ohio, April 4, 2024 /PRNewswire/ -- Ezurio, a global leader in connectivity, today announces the upcoming Sona™ MT320 , the latest addition to their growing Wi-Fi 6 module portfolio.
  • The Sona MT320 is the first industrial grade Wi-Fi + Bluetooth module based on the segment leading MediaTek Filogic 320 (MT7921) Wi-Fi 6 chipset.
  • This embedded module series has been designed to work seamlessly with the MediaTek Genio processor family targeted at the industrial IoT sector.
  • The Sona MT320 provides a rugged, compact, and globally certified solution that ensures reliable connectivity and easy integration.

iRobot Introduces $275 Roomba Combo® Essential Robot, Letting More Customers Enjoy Simple, Affordable and Powerful 2-in-1 Cleaning

Retrieved on: 
Thursday, April 4, 2024
Apple Inc., OS, Suction, Essential, Roomba, Alexa, Intelligence, CLEAN, IRBT, IRobot, Life, Amazon (company), Water, Vacuum, Siri

BEDFORD, Mass., April 4, 2024 /PRNewswire/ -- iRobot Corp. (NASDAQ: IRBT), a leader in consumer robots, today introduced the Roomba Combo® Essential robot, an affordable and easy-to use 2-in-1 robot vacuum and mop. At $275, the Roomba Combo Essential delivers the cleaning essentials customers loved about the best-selling1 Roomba 600 Series – but with better performance and an impressive set of features that make it even simpler to clean the way they want. The company also announced it has surpassed the milestone of selling more than 50 million robots worldwide.

Key Points: 
  • "As iRobot surpasses more than 50 million robots sold worldwide, we're honoring that legacy with the introduction of the affordable Roomba Combo Essential, which cleans even better and does more than its predecessor.
  • Loaded with cleaning essentials and powered by iRobot OS, the Roomba Combo Essential is iRobot's simplest, most affordable 2-in-1 robot vacuum and mop.
  • Carefully curated features powered by iRobot OS let Roomba Combo Essential customers customize and automate their cleaning routines.
  • The Roomba Vac Essential offers the same intelligence and many of the same great features as the Roomba Combo Essential in a vacuum-only package.

Avassa and OnLogic: Combining Software and Hardware for Industrial IoT Edge Excellence

Retrieved on: 
Wednesday, April 3, 2024
OS, ROI, Organization, Original equipment manufacturer, Partnership, Internet of things, Industrial internet of things, Embedded, AI, Software, Computer, Industrial, Product management, Lidar, Movement, Customer service

STOCKHOLM, April 3, 2024 /PRNewswire/ -- Edge application management and operations platform provider Avassa ( https://avassa.io/ ), and global industrial computer manufacturer OnLogic ( www.onlogic.com ), announce a partnership to offer a full-stack edge solution combining hardware and software tailor-made for industrial IoT edge environments.

Key Points: 
  • STOCKHOLM, April 3, 2024 /PRNewswire/ -- Edge application management and operations platform provider Avassa ( https://avassa.io/ ), and global industrial computer manufacturer OnLogic ( www.onlogic.com ), announce a partnership to offer a full-stack edge solution combining hardware and software tailor-made for industrial IoT edge environments.
  • Combining OnLogic and Avassa, organizations benefit from a full-stack edge solution spanning hardware and software that is purpose-built for edge environments.
  • We often talk to customers who are building a new generation of IoT edge infrastructure, and that includes both edge computers and a software platform for managing edge and IoT applications.
  • This requires next-generation combined software and hardware industrial IoT solutions that meet and exceed these demands.

Avassa and OnLogic: Combining Software and Hardware for Industrial IoT Edge Excellence

Retrieved on: 
Wednesday, April 3, 2024
OS, ROI, Organization, Original equipment manufacturer, Partnership, Internet of things, Industrial internet of things, Embedded, AI, Software, Computer, Industrial, Product management, Lidar, Movement, Customer service

STOCKHOLM, April 3, 2024 /PRNewswire/ -- Edge application management and operations platform provider Avassa ( https://avassa.io/ ), and global industrial computer manufacturer OnLogic ( www.onlogic.com ), announce a partnership to offer a full-stack edge solution combining hardware and software tailor-made for industrial IoT edge environments.

Key Points: 
  • STOCKHOLM, April 3, 2024 /PRNewswire/ -- Edge application management and operations platform provider Avassa ( https://avassa.io/ ), and global industrial computer manufacturer OnLogic ( www.onlogic.com ), announce a partnership to offer a full-stack edge solution combining hardware and software tailor-made for industrial IoT edge environments.
  • Combining OnLogic and Avassa, organizations benefit from a full-stack edge solution spanning hardware and software that is purpose-built for edge environments.
  • We often talk to customers who are building a new generation of IoT edge infrastructure, and that includes both edge computers and a software platform for managing edge and IoT applications.
  • This requires next-generation combined software and hardware industrial IoT solutions that meet and exceed these demands.